Vassilios Myrianthopoulos

List of Publications by Year
in descending order

46 papers	1,605 citations	393982 19 h-index	329751 37 g-index
48 all docs	48 docs citations	48 times ranked	2687 citing authors

#	Article	IF	Citations
1	Novel Aryl-Substituted Pyrimidones as Inhibitors of 3-Mercaptopyruvate Sulfurtransferase with Antiproliferative Efficacy in Colon Cancer. Journal of Medicinal Chemistry, 2021, 64, 6221-6240.	2.9	14
2	Cockayne Syndrome Group B (CSB): The Regulatory Framework Governing the Multifunctional Protein and Its Plausible Role in Cancer. Cells, 2021, 10, 866.	1.8	9
3	The Role of E3, E4 Ubiquitin Ligase (UBE4B) in Human Pathologies. Cancers, 2020, 12, 62.	1.7	20
4	Screening of Heteroaromatic Scaffolds against Cystathionine Beta-Synthase Enables Identification of Substituted Pyrazolo[3,4-c]Pyridines as Potent and Selective Orthosteric Inhibitors. Molecules, 2020, 25, 3739.	1.7	2
5	Lipophilic Guanylhydrazone Analogues as Promising Trypanocidal Agents: An Extended SAR Study. Current Pharmaceutical Design, 2020, 26, 838-866.	0.9	4
6	Senescence and senotherapeutics: a new field in cancer therapy. , 2019, 193, 31-49.		116
7	Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule mining. , 2019, 203, 107395.		76
8	Design, synthesis and biological evaluation of novel substituted purine isosters as EGFR kinase inhibitors, with promising pharmacokinetic profile and inÂvivo efficacy. European Journal of Medicinal Chemistry, 2019, 176, 393-409.	2.6	13
9	Scaffold hybridization strategy towards potent hydroxamate-based inhibitors ofFlaviviridaeviruses andTrypanosomaspecies. MedChemComm, 2019, 10, 991-1006.	3.5	9
10	Investigating and re-evaluating the role of glycogen synthase kinase 3 beta kinase as a molecular target for cardioprotection by using novel pharmacological inhibitors. Cardiovascular Research, 2019, 115, 1228-1243.	1.8	25
11	Indirubin Analogues Inhibit Trypanosoma brucei Glycogen Synthase Kinase 3 Short and T. brucei Growth. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	5
12	A Novel Quantitative Method for the Detection of Lipofuscin, the Main By-Product of Cellular Senescence, in Fluids. Methods in Molecular Biology, 2019, 1896, 119-138.	0.4	11
13	From bench to bedside, via desktop. Recent advances in the application of cutting-edge in silico tools in the research of drugs targeting bromodomain modules. Biochemical Pharmacology, 2019, 159, 40-51.	2.0	0
14	Immunohisto(cyto)chemistry: an old time classic tool driving modern oncological therapies. Histology and Histopathology, 2019, 34, 335-352.	0.5	7
15	Selective cytotoxicity of the herbal substance acteoside against tumor cells and its mechanistic insights. Redox Biology, 2018, 16, 169-178.	3.9	37
16	A facile consensus ranking approach enhances virtual screening robustness and identifies a cell-active DYRK1Î± inhibitor. Future Medicinal Chemistry, 2018, 10, 2411-2430.	1.1	6
17	The emerging field of senotherapeutic drugs. Future Medicinal Chemistry, 2018, 10, 2369-2372.	1.1	24
18	In Silico Screening of Compound Libraries Using a Consensus of Orthogonal Methodologies. Methods in Molecular Biology, 2018, 1824, 261-277.	0.4	5

#	Article	IF	Citations
19	NmeA, a novel efflux transporter specific for nucleobases and nucleosides, contributes to metal resistance in Aspergillus nidulans. Molecular Microbiology, 2017, 105, 426-439.	1.2	3
20	Synthesis, Docking Study and Kinase Inhibitory Activity of a Number of New Substituted Pyrazolo[3,4-<i>c</i>]pyridines. Chemical and Pharmaceutical Bulletin, 2017, 65, 66-81.	0.6	9
21	Combined Virtual and Experimental Screening for CK1 Inhibitors Identifies a Modulator of p53 and Reveals Important Aspects of in Silico Screening Performance. International Journal of Molecular Sciences, 2017, 18, 2102.	1.8	8
22	Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration Analysis. Journal of Medicinal Chemistry, 2016, 59, 8787-8803.	2.9	41
23	Natural-Based Indirubins Display Potent Cytotoxicity toward Wild-Type and T315I-Resistant Leukemia Cell Lines. Journal of Natural Products, 2016, 79, 2464-2471.	1.5	14
24	Screening of a composite library of clinically used drugs and well-characterized pharmacological compounds for cystathionine Î²-synthase inhibition identifies benserazide as a drug potentially suitable for repurposing for the experimental therapy of colon cancer. Pharmacological Research, 2016, 113, 18-37.	3.1	62
25	Tandem virtual screening targeting the SRA domain of UHRF1 identifies a novel chemical tool modulating DNA methylation. European Journal of Medicinal Chemistry, 2016, 114, 390-396.	2.6	34
26	Exploring and exploiting the systemic effects of deregulated replication licensing. Seminars in Cancer Biology, 2016, 37-38, 3-15.	4.3	41
27	Novel indoleâ€“flutimide heterocycles with activity against influenza PA endonuclease and hepatitis C virus. MedChemComm, 2016, 7, 447-456.	3.5	24
28	Indirubins: A Potential Therapeutic Target in Multiple Myeloma. Blood, 2016, 128, 3259-3259.	0.6	0
29	Discovery of the Glycogen Phosphorylase-Modulating Activity of a Resveratrol Glucoside by Using a Virtual Screening Protocol Optimized for Solvation Effects. Planta Medica, 2015, 81, 507-516.	0.7	7
30	An inhibitor-driven study for enhancing the selectivity of indirubin derivatives towards leishmanial Glycogen Synthase Kinase-3 over leishmanial cdc2-related protein kinase 3. Parasites and Vectors, 2014, 7, 234.	1.0	33
31	Impact of binding site waters on inhibitor design: contemplating a novel inverse binding mode of indirubin derivatives in DYRK kinases. Journal of Cheminformatics, 2014, 6, .	2.8	0
32	Novel Inverse Binding Mode of Indirubin Derivatives Yields Improved Selectivity for DYRK Kinases. ACS Medicinal Chemistry Letters, 2013, 4, 22-26.	1.3	65
33	Modeling, Substrate Docking, and Mutational Analysis Identify Residues Essential for the Function and Specificity of a Eukaryotic Purine-Cytosine NCS1 Transporter. Journal of Biological Chemistry, 2012, 287, 36792-36803.	1.6	39
34	Identification of the Substrate Recognition and Transport Pathway in a Eukaryotic Member of the Nucleobase-Ascorbate Transporter (NAT) Family. PLoS ONE, 2012, 7, e41939.	1.1	42
35	Identification of a Substrate Translocation Trajectory in the Inward-Facing Conformation of the Monocarboxylate/H+ Symporter Jen1. Biophysical Journal, 2011, 100, 246a.	0.2	0
36	A substrate translocation trajectory in a cytoplasmâ€facing topological model of the monocarboxylate/H⁺ symporter Jen1p. Molecular Microbiology, 2011, 81, 805-817.	1.2	30

#	Article	IF	Citations
37	Design and synthesis of new C-nucleosides as potential adenosine deaminase inhibitors. Tetrahedron, 2010, 66, 9620-9628.	1.0	14
38	Two New Peltogynoids fromAcacia niloticaDelile with Kinase Inhibitory Activity. Planta Medica, 2010, 76, 458-460.	0.7	31
39	6-Br-5methylindirubin-3â€²oxime (5-Me-6-BIO) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: Exploitation of GSK-3 for treating leishmaniasis. International Journal for Parasitology, 2009, 39, 1289-1303.	1.3	67
40	Synthesis of 1,2-annulated adamantane heterocycles: structural determination studies of a bioactive cyclic sulfite. Tetrahedron Letters, 2009, 50, 2671-2675.	0.7	11
41	Roscovitine-Derived, Dual-Specificity Inhibitors of Cyclin-Dependent Kinases and Casein Kinases 1. Journal of Medicinal Chemistry, 2008, 51, 5229-5242.	2.9	124
42	Sesquiterpene Lactones fromStaehelina fruticosa. Journal of Natural Products, 2008, 71, 847-851.	1.5	11
43	Soluble 3â€²,6-Substituted Indirubins with Enhanced Selectivity toward Glycogen Synthase Kinase -3 Alter Circadian Period. Journal of Medicinal Chemistry, 2008, 51, 6421-6431.	2.9	105
44	Chemical Composition Of The Essential Oil OfCionura Erecta(Asclepiadaceae) Inforescences. Journal of Essential Oil Research, 2007, 19, 266-268.	1.3	4
45	An Integrated Computational Approach to the Phenomenon of Potent and Selective Inhibition of Aurora Kinases B and C by a Series of 7-Substituted Indirubins. Journal of Medicinal Chemistry, 2007, 50, 4027-4037.	2.9	60
46	Structural Basis for the Synthesis of Indirubins as Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 and Cyclin-Dependent Kinases. Journal of Medicinal Chemistry, 2004, 47, 935-946.	2.9	343